


AUTHOR QUERY FORM

 ELSEVIER	Journal: TJOG	Please e-mail or fax your responses and any corrections to:
	Article Number: 82	E-mail: corrections.esch@elsevier.tnq.co.in Fax: +31 2048 52789

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof.

Location in article	Query / Remark: Click on the Q link to find the query's location in text Please insert your reply or correction at the corresponding line in the proof
Q1	Please check all author names and affiliations and correct if necessary.
Q2	Please provide the department names in affiliations b, c, g, and h.
Q3	Please provide the department name and complete postal address in the corresponding author section.
Q4	Please check the edits made to the sentence "Traditional Chinese medicines have..."
Q5	Please check the edits made to the sentence "With the rapid increase in..." and correct if necessary.
Q6	Please check the drugs mentioned in the sentence "Compared with other approved..." and provide the manufacturer name and location if they are proprietary names. Also check other edits made to the sentence "With the rapid increase in..." and correct if necessary.
Q7	Please mention what "c-jun, bax, and bcl-2" refer to in the sentence "These neuroprotective effects may..."
Q8	Please check the insertion of the citation for Fig. 3 in the sentence "It is well known that..." and correct if necessary. Please check other edits made to the same sentence.
Q9	Please provide the definition for cAMP in the sentence "The polygalasaponins in the..."
Q10	Please check the edits made to the sentence "Interestingly, recent studies have..." and correct if necessary. Please mention what "tau" refers to in the same sentence and in the subsequent sentence.
Q11	As per journal style, the names of the first six authors should be given followed by "et al." Please provide the names of the first six authors in references 14, 31–33, and 51 if applicable.
Q12	Please provide the citation for Ref. 36 in text and correct if necessary.
Q13	Please check the journal title in Ref. 44 and correct if necessary.
Q14	Please provide the volume number in Ref. 45.
Q15	Please check the edits made to Fig. 2 caption and correct if necessary.

Q16

Please check the sentence “The chemical structure of ginkgo...” for clarity of thought and correct if necessary.

Thank you for your assistance.



Review Article

Traditional Chinese medicines and Alzheimer's disease

Tzong Yuan Wu^{a,b,c}, Chih Ping Chen^{d,e,f,g,h,i}, Tzzy-Rong Jinn^{g,*}^a Department of Bioscience Technology, Chung Yuan Christian University, Chung Li, Taiwan^b Center for Nanotechnology, Chung Yuan Christian University, Chung Li, Taiwan^c R&D Center of Membrane Technology, Chung Yuan Christian University, Chung Li, Taiwan^d Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan^e Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan^f Department of Biotechnology, Asia University, Taichung, Taiwan^g School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan^h Institute of Clinical and Community Health Nursing, National Yang-Ming University, Taipei, Taiwanⁱ Department of Obstetrics and Gynecology, School of Medicine, National Yang-Ming University, Taipei, Taiwan

Accepted 10 January 2011

Abstract

Traditional Chinese medicines have been widely investigated for the treatment of Alzheimer's disease (AD) because none of the current therapies—either the cholinesterase inhibitors or antagonist of *N*-methyl-D-aspartate receptors—has profound effects on halting the progression of AD. In recent years, scientists have isolated many active compounds from herbs, which can alleviate dementia and neurodegenerative syndrome with fewer side effects than conventional drugs and, thus, are regarded as promising drug candidates for AD therapy. In this review, we summarize the latest research progress on six herbs for AD therapy—*Huperzia serrata*, *Amaryllidaceae* family, *Ginkgo biloba*, *Uncaria rhynchophylla*, *Polygala tenuifolia*, and *Salvia officinalis*—and focus on the analysis of their active components and possible mechanisms of pharmacological actions on AD.

Copyright © 2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.

Keywords: Alzheimer's disease; Acetylcholinesterase; Cognitive impairment; Dementia; Neuroprotection; Traditional Chinese medicine

Introduction

With the rapid increase in the aged population in recent years, senile dementia has become one of the world's important public health issues. Alzheimer's disease (AD) is the most common type of senile dementia, a neurodegenerative disease characterized by progressive memory loss and cognitive impairment in the elderly [1]. Pathological characterization of AD includes extracellular deposition of senile plaques; formation of intracellular neurofibrillary tangles; and lesions of cholinergic neurons together with synaptic alterations in cerebral cortex, hippocampus, and other brain regions [2]. At

present, it is well accepted that multiple factors involved in the progress of AD are apoptosis, oxidative stress, mitochondrial dysfunction, inflammatory responses, and disturbance of energy metabolism homeostasis. However, the severe loss of function of the cholinergic neurons correlating with dementia in AD is still not clearly understood [3]. Current clinical drugs administered to slow down the progress of the deterioration in AD patients include cholinesterase inhibitors and agonists of *N*-methyl-D-aspartate receptors (NMDA) [4], but none of these therapies has profound effects on halting the advancement of AD. As a consequence, it is very important to identify novel and pharmacotherapeutic drugs for AD.

Traditional Chinese medicine (TCM) is practiced in the Chinese health care system for more than 2,000 years. Many active pharmacological compounds from Chinese herbal medicines have been identified for the treatment of various diseases, including diabetes, microbial infections, allergy,

* Corresponding author. Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan.

E-mail address: jinn@mail.cmu.edu.tw (T.-R. Jinn).

inflammation, and cancer. In addition, many Chinese herbs have been claimed to enhance human health by stimulating blood circulation and by supplementing vital energy. Thus, Chinese herbs provide a good source of drugs for screening that may be beneficial for AD patients. In recent years, scientists have isolated many novel compounds from herbs, some of which improve dementia with fewer side effects than conventional drugs and are regarded as promising anti-AD drugs. In this review, we summarize the latest research progress on Chinese herbal medicines showing their possible pharmacological actions in alleviating dementia and AD.

Huperzia serrata (Qian Ceng Ta)

Huperzia serrata has been traditionally used to relieve pain and as an antidote for poisoning as well as for the treatment of contusions, strains, swelling, and schizophrenia. It has been found that active compounds—the *Lycopodium* alkaloids—from *H. serrata* include huperzine A (Hup A, Fig. 1); huperzine B (Hup B); *N*-methyl-Hup B; huperzine; carinatamin A; and carinatamine B [5], and among these, Hup A is considered the most potent acetylcholinesterase (AChE) inhibitor. Hup A had been approved by the Food and Drug Administration to treat AD in the 1990s. Compared with other approved drugs, such as tacrine, donepezil, galanthamine, and rivastigmine, Hup A not only exhibits the most powerful activity as an anti-AChE agent, it also acts better in penetrating the blood–brain barrier. Besides, it also shows higher oral bioavailability and has longer duration of anti-AChE activity [6]. More interestingly, Hup A is also found to be an effective cognition enhancer. It has been demonstrated that Hup A exerts multiple neuroprotective effects, in which the mechanisms may involve the activation of both muscarinic and nicotinic acetylcholine receptors; enhancement of the production of neurotrophic factors; as well as blocking of overstimulated NMDA receptors. It has also been known to regulate the activity of antioxidative enzymes, to attenuate mitochondrial dysfunction, and to scavenge reactive oxygen species [7]. Therefore, Hup A is effective in improving cognitive impairments in multi-infarct dementia, brain trauma, schizophrenia, and benign senescent forgetfulness [6]. These neuroprotective effects may be the result of the upregulation of c-jun and bax as well as the downregulation of bcl-2 [8,9]; the upregulation of nerve growth factor secretion and its downstream signaling; the inhibition of oxidative stress; and the




Fig. 1. The chemical structure of huperzine A isolated from the club moss *Huperzia Serrata*, known as Qian Ceng Ta. The club moss is usually found in deep-shaded forests. Traditional Chinese medicine has used this plant in tea for centuries to heal a variety of illnesses, including seizures, brain swelling, fevers, and inflammation.

improvement in energy metabolism [10]. More importantly, Hup A can modulate the processing of amyloid precursor protein (APP) by the regulation of protein kinase C [11] and the promotion of the nonamyloidogenic pathway of APP metabolism and reduction in the production of A β amyloid. Clinical studies have demonstrated that Hup A can significantly improve the memory of elderly people and AD patients without any notable side effects [12]. In summary, all the advantageous effects of Hup A may be attributed to its potent, reversible, and selective inhibition of AChE [13,14]. Its potency in AChE inhibition is adequate to treat AD and other relevant cognitive impairments.

Amaryllidaceae family

Plants belonging to the Amaryllidaceae family have been traditionally used in China for the treatment of poisonous snakebites, acute laryngeal infection, rheumatoid arthritis, paralysis, and muscle diseases brought about by infantile paralytic sequela [15]. One of the well-studied alkaloids from Amaryllidaceae is galanthamine (Fig. 2), which is a tertiary alkaloid originally extracted from the bulbs of *Galanthus woronowii*. Galanthamine was also isolated from other herbs of the Amaryllidaceae family, such as *Lycoris radiata*, *Lycoris aruaea*, and *Lycoris squamigerica* [16]. It acts as a selective, reversible, and competitive inhibitor of AChE. Previous studies have indicated that galanthamine may potentiate memory deficits [16,17]. Furthermore, the compound has the ability to selectively stimulate or/and modulate neuronal nicotinic acetylcholine receptor, which could facilitate an increase in the synthesis of neurotrophic factors and protect neuronal cells against hazardous effects of oxidative stress and injury [18,19]. Moreover, the combination of galanthamine and nicotine works synergistically in inhibiting microglia activation [20]. A clinical trial has confirmed the efficacy and safety of galanthamine in the treatment of AD [21]. Thus, the use of galanthamine for the treatment of mild to moderate AD has been approved by the State Food and Drug Administration in China and the Food and Drug Administration in the United States. Generally, galanthamine is a natural product with multiple molecular targets as it acts in the regulation of cholinergic transmission and in easing oxidative stress [22];




Fig. 2. The chemical structure of galanthamine extracted from the bulbs of *Galanthus woronowii*, plants of the Amaryllidaceae family, which have been customarily used in Traditional Chinese medicine for the treatment of poisonous snakebites, acute laryngeal infection, rheumatoid arthritis, paralysis, and muscle diseases brought on by infantile paralytic sequela.

potentiates the NMDA response [23–25]; and upregulates the antiapoptotic protein expression [26–28].

Ginkgo biloba

Ginkgo biloba L. has customarily been used in China as a medicine to promote vitality in humans. It is well known that many active components exist in *G. biloba* L.; a few of them are ginkgolides, bilobalide, ginkgolic acids, and ginkgo flavone glycoside (Fig. 3) [29]. It is noteworthy to cite that the leaf extract of *G. biloba* (EGb), labeled EGb761, possesses the capacity to treat a variety of neurological disorders, including AD and age-related dementia [30]. EGb761 is a mixture of flavonoids, terpenes, and organic acids. It was reported that the antioxidant activity of EGb761 may play a substantial role in neuroprotection by decreasing bax/bcl-2 ratios [31], reversal of ischemia-induced reductions of cyclooxygenase III mRNA in hippocampal CA1 neurons, inhibition of nitric oxide synthesis, scavenging of free radicals, and attenuation of lipid peroxidation [32,33]. Consistent with the aforementioned findings, many experimental evidences have demonstrated that EGb761 has many pharmacological effects, including amelioration of mitochondrial dysfunction, blockade of the NMDA receptor, scavenging of free radicals, lowering of oxidative stress, reduction of neural damages, reduction of platelet aggregation, anti-inflammation, and anti-aging [34,35].

Uncaria rhynchophylla

Uncaria rhynchophylla Havil is a medicinal plant that has been used to alleviate neuropsychiatric symptoms, such as headache, dizziness, vertigo, and tinnitus. The extracts of this herb contains several different compounds, such as corynoxine, rhynchophylline, isorhynchophylline, isocorynoxine, geissoschizine methyl ether, hirsuteine, and hirsutine. Some of these mentioned alkaloids have been regarded as neuroprotective compounds [37]. Because one of the etiologies of AD is progressive deposition of insoluble highly neurotoxic A β proteins in the form of senile plaques in the central nervous system [38], attractive therapeutic strategies for the treatment of AD would be the following: inhibition of A β




Fig. 3. The chemical structure of ginkgo flavone glycoside, including kaempferol, quercetin (rutin), and isorhamnetin, extracts from *Ginkgo biloba* L. *Ginkgo biloba* L. has long been used in China as a traditional medicine to promote the vital energy of humans. R=O: kaempferol-3-O-rutinoside; R=OH: quercetin-3-O-O-rutinoside (rutin); R=OCH₃: isorhamnetin-3-O-rutinoside.

generation, prevention of A β fibril formation, or destabilization of preformed A β fibrils. It was reported that the extracts from *U. rhynchophylla* have significant inhibitory and destabilizing effects on A β fibril than other Chinese medical herbs [39]. Hence, *U. rhynchophylla* could have the potential to be a novel therapeutic agent for AD prevention in the future.

Polygala tenuifolia

Herbal medicines have long been used for improving cognitive functions and for the treatment of memory loss. Of these, *P. tenuifolia* Willdenow is one of the most frequently used medicinal herbs for memory loss in TCM. In addition, *P. tenuifolia* has been known to have therapeutic effects, such as expectorant, sedative, antipsychotic, and anti-inflammatory [40]. The polygalasaponins in the dried root of *P. tenuifolia* plant can inhibit cAMP activity [41]. In addition to this, it was accounted that an effective compound from the dried root of *P. tenuifolia*, tenuifolin, could inhibit AchE activity or could enhance cholinergic neurotransmission [42]. It had also been reported that tenuifolin could penetrate the blood–brain barrier and improve cognitive impairment through elevation of the cholinergic system by blocking acetylcholine hydrolysis [42]. Moreover, a decrease in the secretion of A β _{1–40} and A β _{1–42} by tenuifolin was also reported [43]. These important findings will facilitate the development of tenuifolin or its derivatives as pharmaceuticals in the treatment and management of AD.

Salvia officinalis

Salvia officinalis L. is a multifunctional Chinese medicine herb. It has a longstanding application as an antibiotic, antihydrotic, astringent, and antifungal agent. The plant, *S. officinalis*, is well known for its antioxidative properties [44] for the reason that its leaf extract has its main constituent, ursolic acid (Fig. 4), a pentacyclic triterpenoid carboxylic acid, which can effectively reduce the level of lipid peroxidation and efficiently reverse D-galactose-induced learning and memory impairment [45]. Because oxidative stress is linked with damage and progressive cell death occurring in neurodegenerative disorders, such as Parkinson's disease and AD [46], a recent clinical trial had demonstrated that the extracts of *S. officinalis* are effective in treating mild to moderate AD [47]. Moreover, ursolic acid also efficaciously inhibits AchE activity *in vitro* [48]. These results implied that the extracts of *S. officinalis* can be beneficial to AD patients through




Fig. 4. The chemical structure of ursolic acid, a pentacyclic triterpenoid carboxylic acid, which can effectively reduce the level of lipid peroxidation and efficiently reverse D-galactose-induced learning and memory impairment.

protection of neurons by reducing oxidative stress and boosting memory through inhibitions of AchE activity. Likewise, rosmarinic acid, a phenolic derivative of caffeic acid, is also found in water extracts of *S. officinalis*, which exhibits a dose-dependent stalling of the A β fibril formation from A β _{1–40} and A β _{1–42} as well as A β fibril aggregation, and it can also destabilize the integrity of A β fibrils [49,50]. Thus, the *S. officinalis* L. extract could be a promising drug candidate for dementia and AD therapy.

Conclusion

The treatment of AD remains a challenge in the modern day medicine because of the incomplete understanding of its pathogenesis, and still, none of the current therapeutic modalities can successfully halt the progression of AD at an early stage. Thus, perpetual extensive studies to search for new active extracts or components derived from various plants for the treatment of AD are carried out. Indeed, some active extracts or components from herbs are highly potent and multitargeted with low toxicity for the treatment of AD, although the underlying molecular mechanisms have not been fully elucidated. These herbs are regarded as new and promising sources of potential anti-AD drugs. Generally, these encouraging preclinical and clinical trials suggest that TCM is a promising candidate for the treatment of neurodegenerative diseases, such as dementia and AD. This “conventional” TCM also provides a new direction in drug development to obtain advanced therapeutic agents that possess both high efficacy and safety for the treatment of AD other than the conventional “western” medicine. Interestingly, recent studies have implicated memantine, an analog of amantadine, which can inhibit the internal ribosome entry site (IRES) of piconavirus-mediated translation [51] and can also prevent the expression of APP and tau through the inhibition of a translation initiation mechanism that is mediated by the IRES [52,53]. The IRES of tau and APP could be new targets to screen the TCM that can act as potential therapeutic drugs for AD.

Uncited reference

[36].

References

- Wancata J, Musalek M, Alexandrowicz R, Krautgartner M. Number of dementia suffers in Europe between the years 2000 and 2050. *Eur Psychiatry* 2003;18:306–13.
- Fantini J, Yahi N. Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases. *Expert Rev Mol Med* 2010;12:27.
- Lin HQ, Ho MT, Lau LS, Wong KK, Shaw PC, Wan CC. Anti-acetylcholinesterase activities of traditional Chinese medicine for treating Alzheimer's disease. *Chem Biol Interact* 2008;175:352–4.
- Shoji M. Drug therapy for Alzheimer's disease. *Brain Nerve* 2010;62:777–85.
- Ma X, Tan C, Zhu D, Gang DR, Xiao P. Huperzine A from *Huperzia* species—an ethnopharmacological review. *J Ethnopharmacol* 2007;113:15–34.
- Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. *Acta Pharmacol Sin* 2006;27:1–26.
- Zhang HY, Tang XC. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. *Trends Pharmacol Sci* 2006;27:619–25.
- Wang R, Tang XC. Neuroprotective effects of huperzine A: a natural cholinesterase inhibitor for the treatment of Alzheimer's disease. *Neurosignals* 2005;14:71–8.
- Hualiang J, Xiaomin L, Donglu B. Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional Chinese medicine origin for the treatment of Alzheimer's disease. *Curr Med Chem* 2003;10:2231–52.
- Gao X, Tang XC. Huperzine A attenuates mitochondrial dysfunction in beta-amyloid-treated PC12 cells by reducing oxygen free radicals accumulation and improving mitochondrial energy metabolism. *J Neurosci Res* 2006;83:1048–57.
- Zhang HY, Yan H, Tang XC. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells. *Neurosci Lett* 2004;360:21–4.
- Yang CY, Lv ZP, Zheng CG. Efficacy and reliability of huperzine A in mild and moderate Alzheimer's disease. *Chin J Clin Rehabil* 2003;7:4258–9.
- Tang LL, Wang R, Tang XC. Effects of huperzine A on secretion of nerve growth factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC12 cells. *Acta Pharmacol Sin* 2005;26:673–8.
- Wang ZF, Tang LL, Yan H, et al. Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. *Pharmacol Biochem Behav* 2006;83:603–11.
- Tang XC, Jin GZ, Xu B. Neuropharmacologic actions of lycoramine and galanthamine. *Acta Pharm Sin* 1963;10:465–73.
- Wang Y, Huang L, Tang X, Zhang H. Retrospect and prospect of active principle from Chinese herbs in the treatment of dementia. *Acta Pharm Sin* 2010;31:649–64.
- Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. *Neuroscience* 2000;99:17–23.
- Belluardo N, Mudo G, Blum M, Fuxe K. Central nicotinic receptors, neurotrophic factors and neuroprotection. *Behav Brain Res* 2000;113:21–34.
- Shimohama S, Greenwald DL, Shafron DH, Akaika A, Maeda T, Kaneko S, et al. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. *Brain Res* 1998;779:359–63.
- Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, Shytle D, et al. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. *Brain Res Bull* 2004;64:165–70.
- Repantis D, Laisney O, Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. *Pharmacol Res* 2010;61:473–81.
- Ezoulin MJ, Ombetta JE, Dutertre-Catella H, Warnet JM, Massicot F. Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells. *Neurotoxicology* 2008;29:270–7.
- Cao XZ, Zhang LM, Shen YE, Zhou SS, Jiang GH. NMDA receptors mediate the effect of galantamin on the cognitive function of Alzheimer's disease in rats. *J Apop Nerv Dis* 2006;23:678–80.
- Mulder J, Harkany T, Czollner K, Cremers TI, Keijsers JN, Nyakas C, et al. Galantamine-induced behavioral recovery after sublethal excitotoxic lesions to the rat medial septum. *Behav Brain Res* 2005;163:33–41.
- Moriguchi S, Marszalec W, Zhao X, Yeh JZ, Narahashi T. Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. *J Pharmacol Exp Ther* 2004;310:933–42.
- Melo JB, Sousa C, Garcao P, Oliveira CR, Agostinho P. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. *Eur J Neurosci* 2009;29:455–64.

- 518 [27] Matharu B, Gibson G, Parsons R, Huckerby TN, Moore SA, Cooper LJ, et al. Galantamine inhibits beta-amyloid aggregation and cytotoxicity. *J Neurol Sci* 2009;280:49–58. 519 520
- 521 [28] Arias E, Ales E, Gabilan NH, Cano-Abad MF, Villarroya M, Garcia AG, et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. *Neuropharmacology* 2004;46:103–14. 522 523 524
- 525 [29] Gertz HJ, Kiefer M. Review about *Ginkgo biloba* special extract EGb 761 (Ginkgo). *Curr Pharm Des* 2004;10:261–4. 526
- 527 [30] Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. Effects of *Ginkgo biloba* in dementia: systematic review and meta-analysis. *BMC Geriatr* 2010;10:1–14. 528 529
- 530 [31] Lu G, Wu Y, Mak YT, et al. Molecular evidence of the neuroprotective effect of *Ginkgo biloba* (EGb761) using bax/bcl-2 ratio after brain ischemia in senescence-accelerated mice, strain prone-8. *Brain Res* 2006; 531 532 533 1090:23–8.
- 534 [32] Calapai G, Crupi A, Firenzuoli F, et al. Neuroprotective effects of *Ginkgo biloba* extract in brain ischemia are mediated by inhibition of nitric oxide synthesis. *Life Sci* 2000;67:2673–83. 535 536
- 537 [33] Eckert A, Kreil U, Kressmann S, et al. Effects of Egb761 *Ginkgo biloba* extract on mitochondrial function and oxidative stress. *Pharmacopsychiatry* 2003;36:15–23. 538 539
- 540 [34] Li FM, Duan XM, Wang JJ, Fang HL. Effects of *Ginkgo biloba* extract on MitoKATP in focal cerebral ischemia-reperfusion rats. *Chin Arch Tradit Chin Med* 2008;26:1462–3. 541 542
- 543 [35] Kasper S, Schubert H. *Ginkgo biloba* extract EGb 761(R) in the treatment of dementia: evidence of efficacy and tolerability. *Fortschr Neurol Psychiatr* 2009;77:494–506. 544 545
- 546 [36] Wang SY, Liu XM, Wang JX, Liu YX, Yuang DX. Effect of EGb on GFAP in focal cerebral ischemia-reperfusion injury rats. *Anatomy Res* 2008;30:115–7 [in Chinese]. 547 548 Q12
- 549 [37] Kang TH, Murakami Y, Takayama H, Kitajima M, Aimi N, Watanabe H, et al. Protective effect of rhynchophylline and isorhynchophylline on in vitro ischemia-induced neuronal damage in the hippocampus: putative neurotransmitter receptors involved in their action. *Life Sci* 2004;76:331–43. 550 551 552
- 553 [38] Wirths O, Malthaup G, Bayer TA. A modified β -amyloid hypothesis: intraneuronal accumulation of the β -amyloid peptide—the first step of a fatal cascade. *J Neurochem* 2004;91:513–20. 554 555
- 556 [39] Fujiwara H, Iwasaki K, Furukawa K, Seki T, He M, Maruyama M, et al. *Uncaria rhynchophylla*, a Chinese medicinal herb, has potent anti-aggregation effects on Alzheimer's beta-amyloid proteins. *J Neurosci Res* 2006;84:427–33. 557 558 559
- 560 [40] Chung IW, Moore NA, Oh WK, O'Neill MF, Ahn JS, Park JB, et al. Behavioural pharmacology of polygalasaponins indicates potential anti-psychotic efficacy. *Pharmacol Biochem Behav* 2002;71:191–5. 561 562
- 563 [41] Kim HM, Lee EH, Lee HJ, Shin SB, Lyu TY, Kim YS, et al. Effect of *Polygala tenuifolia* root extract on the tumor necrosis factor-alpha secretion from mouse astrocytes. *J Ethnopharmacol* 1998;161:201–8. 564 565
- 566 [42] Lv J, Jia H, Jiang Y, Ruan Y, Liu Z, Yue W, et al. Tenuifolin, an extract derived from tenuigenin, inhibits amyloid- β secretion in vitro. *Acta Physiol* 2009;196:419–25. 567 568
- 569 [43] Jia H, Jiang Y, Ruan Y, Zhang Y, Ma X, Zhang J, et al. Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid beta-protein in cultured cells. *Neurosci Lett* 2004;367:123–8. 570 571
- 572 [44] Schwarz K, Ternes W. Antioxidative constituents of *Rosmarinus officinalis* and *Salvia officinalis*. *Z Lebensm Unters Forsch* 1992;195: 573 574 Q13 99–103.
- 575 [45] Lu J, Zheng YL, Wu DM, Luo L, Sun DX, Shan Q. Ursolic acid ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by D-galactose. *Biochem Pharmacol*; 2007:1078–90. 576 577 Q14
- 578 [46] Sofic E, Sapanin A, Tahirovic I, Gavrankapetanovic I, Jellinger K, Reynolds GP, et al. Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. *J Neural Transm Suppl* 2006;71: 579 580 39–43.
- 581 [47] Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. *Salvia officinalis* extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. *J Clin Pharm Ther* 2003;28:53–9. 582 583 584
- 585 [48] Chung YK, Heo HJ, Kim EK, Kim HK, Huh TL, Lim Y. Inhibitory effect of ursolic acid purified from *Origanum majorana* L on the acetylcholinesterase. *Mol Cells* 2001;11:137–43. 586 587 588
- 589 [49] Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. *Chem Biol Drug Des* 2006;67:23–37. 590 591 592
- 593 [50] Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloiaogenic effects for Alzheimer's beta-amyloid fibrils in vitro. *J Neurosci Res* 2004;75:742–50. 594 595
- 596 [51] Chen YJ, Zeng SJ, Hsu JT, et al. Amantadine as a regulator of internal ribosome entry site. *Acta Pharmacol Sin* 2008;29:1327–33. 597 598
- 599 [52] Wu TY, Chen CP. Dual action of memantine in Alzheimer disease: a hypothesis. *Taiwan J Obstet Gynecol* 2009;48:273–7. 600 601
- 602 [53] Wu TY, Chen CP, Jinn TR. Alzheimer's disease: aging, insomnia and epigenetics. *Taiwan J Obstet Gynecol* 2010;49:468–72. 603 604